Gunderson Dettmer represented client ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, in its $17 million financing led by Longwood Fund.

In the announcement of the transaction, co-founder of ImmuneID Stephen Elledge, Ph.D. said, “High-quality therapeutic target identification has remained a vexing bottleneck in drug discovery. The ImmuneID platform, including the VirScan technology, relieves this bottleneck by using its massively parallel, multiplexed, and unbiased approach to provide previously unavailable insight into human immune responses throughout the course of disease progression.”

The Gunderson deal team was led by Tim Ehrlich and included George Pothoulakis, Christopher Sintetos and Blake Rowe.